Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MSU38225 |
Synonyms | |
Therapy Description |
MSU38225 is an Nrf2 inhibitor, potentially inhibiting Nrf2 transcriptional activity and cancer cell growth (PMID: 34158350). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MSU38225 | MSU-38225|MSU 38225 | MSU38225 is an Nrf2 inhibitor, potentially inhibiting Nrf2 transcriptional activity and cancer cell growth (PMID: 34158350). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KEAP1 inact mut | lung adenocarcinoma | sensitive | MSU38225 | Preclinical - Cell culture | Actionable | In a preclinical study, MSU38225 inhibited Nrf2 transcriptional activity and downstream pathway activation, increased Nrf2 degradation, and inhibited growth of lung cancer cells harboring a KEAP1 inactivating mutation in 2D and 3D culture (PMID: 34158350). | 34158350 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|